ICER says most new drug launch prices exceed cost-effectiveness limits

A new analysis from the non-profit ICER found that net launch prices for new medicines spiked significantly between 2022 and 2025, with most prices well above its cost-effectiveness guidelines, according to BioPharma Dive.

This trend puts additional scrutiny on pharma pricing and could prompt stronger responses from payers or regulators. Senior leaders in pharma and healthcare should monitor how these findings may affect reimbursement, access, and pricing negotiations.